Lipocine Inc. · NASDAQ:LPCN
Lipocine — Investor Presentation (March 2026)
7 slides from Lipocine's investor presentation, March 2026
Slide 1: LPCN 2203 Oral NAS for Essential Tremor
LPCN 2203 Oral NAS for Essential Tremor
Slide 2: Essential Tremor (ET): No new drug approved in 50+ years
Essential Tremor (ET) No new drug approved in 50+ years • Tremor highly disabling and stigmatizing • Stress can aggravate tremor in social setting • Major impact on activities of daily living leading to unemployment, anxiety and depression1 • Most common impacts on activities of daily living are pou
Slide 3: ET Patient Journey and Commonly used medications
ET Patient Journey and Commonly used medications • First line treatment of propranolol frequently started at PCP • 2nd and 3rd line treatments (e.g., primidone, benzodiazepine, gabapentin, topiramate) at general neurologist and movement disorder clinics • Patient survey indicates on-going management
Slide 4: Market potential - $3B+ blockbuster opportunity as 2nd line
Essential Tremor (ET) Market potential - $3B+ blockbuster opportunity as 2nd line with 20% peak adoption • Tremor is highly disabling and stigmatizing Estimated prevalence • Stress can aggravate tremor in social setting 2.2 % of population1 ~7 M • Major impact on activities of daily living leading t
Slide 5: Essential Tremor Management – No New Drugs Approved In 50+ Years
Essential Tremor Management – No New Drugs Approved In 50+ Years Daytime efficacy and improved tolerability remain an unmet need Unmet Need Standard of Care Limitations Competitive Landscape Superior benefit to risk profile Unfavorable benefit to risk profile3 • Propranolol is the first line therapy
Slide 6: LPCN Product Target Differentiation
LPCN Product Target Differentiation Favorable benefit to Novel MOA risk profile Daytime efficacy Endogenous NAS Potential to address anxiety and depression comorbidities Corporate Presentation September 2022 Lipocine | 2026 6
Slide 7: Business Development Contacts
Business Development Contacts Kongnara Papangkorn, Ph.D. Business Development Manager kp@lipocine.com